John, 68: A Model Case

A composite patient with an “early Alzheimer’s” diagnosis, and the six parameters no consultation ordered. What the literature says about each in isolation, what the composite trials suggest, what the correction produces, and the funding architecture that arranges for the composite evidence to remain thin. A working brief for jurists reading this site.

John is sixty-eight. He retired three years ago from an engineering firm at which he had worked since his twenties. His wife noticed, two years before the referral, that he was misplacing appointments. His son noticed, six months before the referral, that he was losing words in mid-sentence and repeating the same anecdote across a dinner. His gait, which had been steady all his life, became unsteady on descending stairs. He began to nap in the afternoon in a way he had not before. He began to sit for long periods without speaking. His wife, who had watched her mother go through the same trajectory a decade earlier, made the referral.

The memory clinic runs the standard workup. Structural MRI shows mild hippocampal atrophy consistent with age but at the higher end of the range for the cohort. Neuropsychological testing places him in the mild cognitive impairment band, with characteristic weakness in episodic memory and delayed recall. A CSF tap is discussed and declined by the family. A blood panel is ordered, and returns unremarkable on every axis it examines: full blood count normal, electrolytes normal, renal function normal, liver function normal, glucose and HbA1c normal, TSH normal, serum B12 within reference range at 260 pg/mL.

The neurologist’s letter to the GP records a diagnosis of Alzheimer’s disease, probably-early-stage. A cholinesterase inhibitor is initiated. The family is offered a memory-clinic follow-up in six months. A social worker begins a conversation with John’s wife about power of attorney and about early planning for residential care.

John’s son, who reads too much on the internet according to the neurologist, insists on a wider workup. It is done at a private laboratory, at the family’s expense, over the following month.

Six parameters, which the memory clinic did not order, come back:

• Serum vitamin B12: 260 pg/mL. Methylmalonic acid: 620 nmol/L. Homocysteine: 18 μmol/L.
• Red-cell folate: 210 nmol/L.
• 25-hydroxyvitamin D: 18 ng/mL.
• Free triiodothyronine (fT3): 2.4 pmol/L, at the low end of the reference range. Reverse T3 elevated. Thyroid antibodies negative.
• Omega-3 Index (erythrocyte EPA + DHA): 3.4 %.
• Red-cell magnesium: at the tenth percentile of the reference range, with serum magnesium normal.

Each of these values is either below a widely-recognised functional threshold, or elevated in a direction that signals functional insufficiency of a related pathway. Not one of them is diseased in the axis of the diagnosis the memory clinic reached. Every one of them has independent literature linking it to cognitive decline in an elderly population.

The diagnosis was reached before any of these tests was ordered.

What the memory clinic did, in its own frame, correctly

The memory-clinic workup John received is consistent with the standard of care of every jurisdiction in which the workup would have been done. The MRI was ordered. The neuropsychological battery was administered. The blood panel was ordered. The TSH was included. The clinician’s diagnostic conclusion is one that any neurologist with the same file, reading the same reference ranges, would have reached in the same terms.

Nothing in the standard obliged the clinic to order a methylmalonic acid or a homocysteine. Nothing obliged them to measure red-cell folate rather than serum folate. Nothing obliged them to measure 25-OH-D. Nothing obliged them to look at fT3 or reverse T3 when TSH was in range. Nothing obliged them to measure Omega-3 Index. Nothing obliged them to look at red-cell magnesium.

The doctrinal frame in which none of this was ordered is elaborated in Otherwise Healthy. In brief: the physician’s mental model of a body treats within-reference-range parameters as sufficient, and does not accommodate the possibility that six parameters simultaneously within reference range on the axes checked can conceal a body that is severely undersupplied on the axes not checked. Each individual omission is defensible as a matter of practice economics. The composite of the omissions is the case being described here.

What the literature says about each parameter, in isolation

Vitamin B12 and folate: the homocysteine axis

Homocysteine has been established as an independent risk factor for dementia by the Framingham Heart Study cohort. Seshadri and colleagues reported in the New England Journal of Medicine in 2002 that each increment of 5 μmol/L in plasma homocysteine was associated with a forty percent increase in the risk of Alzheimer’s disease and dementia over eight years of follow-up. The finding has been replicated in subsequent cohorts. Homocysteine is elevated when the methylation cycle is undersupplied at B12, folate, or B6, and the elevation is the marker of a metabolic failure that has neurological consequences.

The Oxford VITACOG trial, published by Smith and colleagues in PLOS ONE in 2010, randomised patients with mild cognitive impairment to a high-dose combination of B12, folate, and B6 or to placebo, for twenty-four months. In the treated group, the rate of whole-brain atrophy was reduced by roughly thirty percent, and the effect was larger, up to fifty-three percent, in patients whose baseline homocysteine was in the upper tertile. Douaud and colleagues reported in PNAS in 2013 that the same B-vitamin treatment substantially reduced grey matter atrophy in the Alzheimer’s-vulnerable regions, with the effect largest in the subgroup with elevated baseline homocysteine. The cognitive outcomes of the same trial, published by de Jager and colleagues in the International Journal of Geriatric Psychiatry in 2012, showed improvements in memory and executive function proportional to the reduction in homocysteine.

Serum B12 at 260 pg/mL is within the haematological reference range. The neurological reference range is different. The rise in methylmalonic acid above 300 nmol/L and homocysteine above 15 μmol/L in John’s file is the biochemical signal of functional B12 insufficiency, regardless of what the serum measurement says. The correction is intramuscular hydroxocobalamin or oral methylcobalamin at a dose adequate to bring the metabolic markers into range, together with a form of folate the patient can convert. Neither was offered.

The rights fiche on folate develops the metabolic argument in full.

Vitamin D

Littlejohns and colleagues reported in Neurology in 2014, on the Cardiovascular Health Study cohort followed over roughly six years, that participants with severe 25-OH-D deficiency (below 25 nmol/L, or roughly 10 ng/mL) had a doubled risk of all-cause dementia and Alzheimer’s disease compared to those with sufficient status. Vitamin D receptors are expressed in the hippocampus and in other regions implicated in the pathogenesis of Alzheimer’s disease. The mechanistic literature on vitamin D and amyloid-β clearance is substantial. The intervention trials at this endpoint are thin, for reasons developed later in this piece, but the observational evidence is well replicated.

John at 18 ng/mL sits above the threshold that would produce the severest risk in the Littlejohns cohort, but is well below any functional target that the mechanistic literature would identify as sufficient. The intervention is oral cholecalciferol at a dose adjusted to bring 25-OH-D above 40 ng/mL and probably above 50, with cofactor attention to magnesium (which is required for D activation) and to vitamin K2 (which regulates calcium partitioning as D-mediated absorption increases). It was not offered.

Thyroid: the T3 problem the TSH does not see

TSH is a pituitary signal, not a peripheral tissue measurement. It is a good screen for primary hypothyroidism where the thyroid gland has failed. It is a poor screen for the states in which conversion of T4 to T3 is impaired at the tissue level: chronic illness, inflammation, elevated cortisol, aging itself. Reverse T3, the inactive isomer that competes with T3 at the receptor, is often elevated in these states. The clinical picture, in the elderly, is a fatigue, apathy, cognitive slowing, and constipation which the guidelines-based TSH-only screen dismisses.

The literature on subclinical thyroid states and cognitive decline is contested, with negative trials in populations of unclear physiological homogeneity, but a fT3 at 2.4 pmol/L with an elevated reverse T3 is not a subclinical state on any physiologically-driven read. It is a state in which the tissue is not receiving what the pituitary thinks it is signalling. In an elderly patient with cognitive decline, the intervention is a trial of T3 substitution, alongside correction of the substrates (iron, selenium, zinc) on which conversion depends. It was not considered.

The rights fiche on optimal hormonal levels develops the argument that a TSH-only endocrinology fails a large class of symptomatic patients.

Omega-3

The Omega-3 Index, the percentage of EPA plus DHA in red-blood-cell membranes, is a measurement whose functional target is above eight percent. Below four percent, the epidemiological association with cardiovascular mortality is well established. The neurological association is separately established. Yurko-Mauro and colleagues reported in Alzheimer’s & Dementia in 2010 the MIDAS trial, in which 900 mg per day of DHA for twenty-four weeks improved memory function in adults with age-related cognitive decline. Soininen and colleagues reported in The Lancet Neurology in 2017 the LipiDiDiet trial, in which a specific multi-nutrient formulation including DHA, EPA, phospholipids, choline, uridine, and B vitamins over twenty-four months in patients with prodromal Alzheimer’s disease showed benefits on secondary outcomes of memory function and hippocampal atrophy while missing the primary composite endpoint.

The mechanistic argument is direct. Neuronal membranes are constructed from the fatty acids the diet supplies. A membrane at 3.4 % EPA + DHA is a membrane in which docosahexaenoic acid, the primary structural fatty acid of the neuronal synapse, has been progressively replaced by n-6 fatty acids that alter fluidity, receptor function, and the resolution of inflammation. The intervention is EPA + DHA at a dose adequate to bring the Index above eight percent, sustained for twelve to eighteen months, alongside reduction in dietary n-6 excess.

The rights fiche on omega-3 develops the substrate argument.

Magnesium

Serum magnesium is normal. Red-cell magnesium at the tenth percentile is not. Magnesium is a cofactor at every phosphorylation event in the Krebs cycle, at the ATPase, at NMDA-receptor modulation, and at hundreds of other reactions on which neuronal function depends. Slutsky and colleagues reported in Neuron in 2010 that a specific magnesium compound elevating brain magnesium in rodents enhanced learning and memory. The human intervention trials are thinner and more contested. The mechanistic literature is not.

The intervention in John’s case is magnesium at a dose and form adequate to raise the intracellular measurement, with attention to the cofactor cascade (B6 for absorption, sufficient protein for cellular delivery). It was not offered.

The full argument is developed in the magnesium fiche.

What the literature says about correcting several at once

The single-nutrient trial is the paradigm of the industry-funded evidence base. It is not the paradigm of the biology. The biology is that a body run below sufficiency on six axes simultaneously is not a body whose function will be restored by correcting one axis in isolation. The mitochondria that cannot make enough ATP because thiamine, riboflavin, magnesium, and iron are each partially insufficient will not be made to work by correcting any one of these. The neuronal membrane that lacks DHA will not compensate for a homocysteine-elevated methylation cycle. Each correction unlocks its own step. The composite unlocks the whole system.

The FINGER trial, reported by Ngandu and colleagues in The Lancet in 2015, tested a multi-domain intervention of diet, exercise, cognitive training, and vascular risk monitoring in at-risk elderly Finnish adults over two years. The composite intervention improved cognition in the primary outcome, in a population selected for being at risk of decline. The design was not a multi-parameter substrate correction of the kind John’s file would require, but the direction of the effect and the biology it implicates are shared. The FINGER model has been extended into successor trials in China (MIND-China), the United States (US-POINTER), and other national settings, all in the same direction.

The LipiDiDiet trial, cited above, tested a specific multi-nutrient formulation in prodromal Alzheimer’s disease over two years. The primary composite endpoint was not met at the pre-specified threshold. The secondary endpoints on hippocampal atrophy, memory function, and disease-progression scoring showed benefit. The prevailing interpretation of a mixed trial like this depends on the reader’s priors. On a paradigm in which only a clean single-endpoint result is credible, the trial is negative. On a paradigm in which the physiological question is whether a correction produces a signal in the direction the biology predicts, the trial confirms the direction.

The Bredesen protocol, described by Bredesen in Aging in 2014 and subsequent publications, is an individualised multi-parameter correction protocol applied in case series with reported reversal of cognitive decline in a majority of participants. The publication has been criticised on methodological grounds: no randomised controlled trial, small numbers, potential selection bias, no placebo arm. The methodological criticism is not fully wrong. It is also not the whole story. The design of a placebo-controlled RCT of an individualised multi-parameter protocol requires either standardising the intervention (which destroys the individualisation on which the biological logic depends) or randomising individualised assignments (which no funder builds). The methodological objection is a filter problem that the funding architecture is structured not to solve.

What happened to John

John’s family, having obtained the six-parameter workup at their expense, brought the results to a private physician who prescribed a corrective regimen calibrated to bring each parameter into a functional range. The regimen included intramuscular hydroxocobalamin followed by daily methylcobalamin and methylfolate, oral cholecalciferol at 5000 IU per day with vitamin K2 and magnesium glycinate, a trial of low-dose T3 substitution alongside selenium, EPA + DHA at 3 g per day, and an anti-inflammatory dietary pattern.

At the three-month reassessment: methylmalonic acid had returned to normal, homocysteine had fallen to 9 μmol/L, 25-OH-D had risen to 44 ng/mL, fT3 was in the upper third of the reference range, Omega-3 Index was 6.1 %, red-cell magnesium at the fortieth percentile. John’s gait had normalised. His afternoon naps had shortened. His wife reported that he was again participating in evening conversation.

At the twelve-month reassessment: cognitive testing at the memory clinic no longer met criteria for mild cognitive impairment. John was reading in the evening again. He had returned to a woodworking hobby he had discontinued four years earlier. He remained on daily supplementation and dietary structure. The neurologist, on reassessment, replaced the diagnosis of probable Alzheimer’s disease with an unspecified category of resolved cognitive impairment. The cholinesterase inhibitor was discontinued.

John is not fictional in any particular. Every element of his trajectory has been observed in the clinical literature and in the case series published under the multi-parameter protocols cited above. What is composite about John is only that all of the elements are combined in one person. In the referral population of any memory clinic in the developed world, some substantial fraction of “early Alzheimer’s” diagnoses sit on a physiological substrate that has never been examined at the granularity John’s private workup examined.

“Too good to be true”

The reflex is understandable. A retired engineer diagnosed with early Alzheimer’s disease returns to baseline cognitive function twelve months after a six-parameter substrate correction, and the reader hears an infomercial. The reflex is a defence against exploitation by the wellness industry, which has produced a steady output of miracle-reversal claims founded on nothing. That industry exists. Its output is real. The reflex is not misplaced.

The reflex is nonetheless the wrong instrument for reading John’s file, because John’s file is not one story. It is six stories, each of them documented in the peer-reviewed literature. Homocysteine elevation is an established risk factor for dementia; its reduction by B-vitamin correction slows brain atrophy at MCI stage; the effect scales with baseline elevation. Vitamin D deficiency doubles all-cause dementia risk in the largest cohort study of the endpoint; the receptors are in the hippocampus. DHA improves memory in age-related decline; membranes rebuild slowly but rebuild. The tissue-level thyroid state that TSH does not see is undertreated in the elderly and produces cognitive symptoms textbook to the field. Magnesium is a cofactor at hundreds of neuronal reactions; its cellular measurement is not the serum measurement, and the cellular measurement is what matters. Each correction produces its own effect. The compounding is not miraculous. It is what happens when a system is undersupplied on multiple axes and receives multiple corrections at once.

The reader who feels the pull of “too good to be true” is being invited to notice what the calibration of that reflex is set to. It is set to a body from which no serious correction is expected because the medical culture into which the reader has been socialised produces almost none. The reflex is a symptom of the frame described in Otherwise Healthy, operating on the reader. Once the frame is seen as a frame, the correction stops looking miraculous. It starts looking like arithmetic.

“If it were true, we’d know”

The other reflex. If the correction were as effective as John’s file suggests, it would be standard of care. It is not standard of care. Therefore either the correction does not work as described, or the medical profession has somehow failed to notice a working intervention across decades. The second premise seems absurd. The first is presumed.

The reasoning is coherent. Its hidden assumption is that the medical profession’s standard of care is the outcome of a search process that would have found the intervention if it worked. That assumption is the assumption undone at length in Rights-Based Medicine vs Evidence-Based Medicine. Standard of care is the outcome of what industry-funded RCTs have proved to a specific evidentiary standard. The RCTs are built where the funding is. The funding is where the licensable molecule is. There is no licensable molecule in a six-substrate correction whose components are on the WHO Model List and available in every pharmacy in the world. There is no engine that would have built the trial. In the absence of the trial, the intervention is filed as not-yet-proven, and standard of care does not update.

This is not conspiracy. It is architecture. The medical profession does not need to have conspired against John’s correction. It only needs to have deferred, systematically and in good faith, to an evidence base whose absences are structural rather than epistemic. What we don’t know is what we haven’t been funded to find out. What we haven’t been funded to find out is what nobody stands to make money on. The intersection is where John’s file has been sitting for decades.

The claim is not that no one in the profession knows. Clinicians who read the primary literature carefully know. The Oxford group knows. Bredesen’s clinical network knows. The FINGER investigators know. There is not a shortage of clinicians who have moved past the frame. There is a shortage of institutional pressure to make what they know the norm. That institutional pressure comes from the outside. It comes, historically and currently, from patient advocacy that has succeeded in translating physiological knowledge into rights. It came for HIV. It came for humanitarian nutrition. It has not yet come for the class of substrates John needed.

The doctrinal precedents for that translation are laid out in The Instruments Already Exist.

Where the right sits

The instrument is the same as for Ferritin 24. Article 12 of the ICESCR, read through General Comment 14. The AAAQ framework requires acceptability and quality of health services calibrated to the person receiving them. John received services measured against the axes the memory clinic ordered, not against the axes his condition required. The core obligations of General Comment 14 include provision of essential goods, operationalisable through the WHO Model List. B12, folate, vitamin D, iron, magnesium are all on the Model List. Their systematic delivery to bodies that measurably need them is not.

Two elements make John’s claim structurally distinct from Jane’s. The first is that John’s harm is compounding across six axes, not one. The rights-based reading of a multi-parameter deficit is not that six independent rights have been infringed, though that could be argued. It is that a single right to physiological integrity has been infringed at six sites simultaneously, and that the compound damage is the substance of the harm.

The second is the irreversibility clock. Where Jane’s iron correction restores her fully at any reasonable time horizon, John’s neurological substrate loses correctability with delay. Every year in which the correction is not offered is a year of progressive neuronal loss whose reversibility narrows toward zero. The State’s obligation to test and correct is heightened by the irreversibility of the harm the delay produces. The precedent for treating irreversibility as an intensifier of positive obligation is present in humanitarian law (irreversible cretinism from maternal iodine deficiency, developed in General Comment 12) and can be extended.

What John would plead

First, that the memory clinic to which he was referred, and by extension the health system that constructed the referral pathway, failed to test the physiological parameters whose composite deficit was producing his symptoms, despite an evidence base linking each of them independently to cognitive decline in his class.

Second, that the diagnostic conclusion reached in the absence of that testing was of a disease category (Alzheimer’s disease) that carries a prognosis of irreversible decline, and that the treatment initiated on that diagnosis (cholinesterase inhibition) does not address any of the physiological substrates on which his condition sits.

Third, that the correction owed to him, calibrated to bring six documentable parameters into a range compatible with the biological substrate on which cognition depends, was not offered, was not considered, and was not present in the standard of care to which the memory clinic conformed.

Fourth, that the omission is not an individual clinical error but a systemic feature of a practice architecture that has been arranged around evidence categories whose absence, in the case of substrates that cannot be licensed as intellectual property, has been produced structurally rather than epistemically. The AAAQ framework fails on acceptability and on quality, and the core obligations of General Comment 14 have been unmet at a compounding cost that any reasonable reading of the ICESCR would treat as a violation.

The remedy sought is an order compelling the health system to test, at the physiological granularity the international literature has already established, the parameters recognised as substrates of cognitive function, and to correct those parameters where deficient, in the population of patients presenting with the clinical picture John presented with. Damages, where a jurisdiction permits them, would be a secondary remedy. The primary remedy is structural.

Where John wins, where he loses, where he opens ground

The jurisdictional map for John is the map already described for Jane. South Africa and Colombia remain the strongest venues for structural orders on positive rights. Brazil is doctrinally welcoming. India’s PIL tradition would receive a systemic challenge on the under-testing of the elderly. The Council of Europe route is exploratory but not closed. Canada, France, and the United States require the case to be reshaped into their doctrinal vocabulary before it can be pleaded.

Two features are proper to John’s case rather than Jane’s. The first is that the affected class is politically weaker: the elderly cognitively-impaired do not organise, and their advocates are their families rather than themselves. A systemic order would need to be sought by patient-family coalitions or by public interest litigators acting for the class. The second is that the remedy would name specific parameters and specific thresholds, drawing on the WHO Model List and on the peer-reviewed literature identified above, and would ask the court to compel the health system to update its clinical protocols to include them.

An order of this shape is not without precedent. Courts have compelled national health systems to include specific pharmaceuticals in reimbursement schedules. The extension to specific measurements and to specific substrate corrections is a doctrinal step in a familiar direction, not a leap into new law.

Why this case, and not another

Ferritin 24 was chosen for its pedestrian character. John’s case is chosen for the opposite reason. It is at the ceiling of what physiological rights can be argued to reach. It sits on the tissue with the highest personal and social cost of loss. It engages the irreversibility clock as a distinct legal argument. It opens the horizon of expectation that a rights-based frame is meant to open.

The horizon is this: a class of “dementias” that would not have been dementias if the substrates had been supplied. Not all dementias. Not most, on any conservative estimate. But an unknown fraction, plausibly substantial, of the diagnoses now being made in memory clinics under the current standard of care would resolve to something else if the multi-parameter workup were done and the correction were offered. What that fraction is, no one knows, because no funder has built the trial that would find out.

The horizon of expectation is what a jurisprudence of physiological rights is being asked to protect. Not the certainty of reversal for every patient. Not the miracle. The chance, verified biologically and confirmed in the small evidence base that has been built despite the funding structure, that the person in front of the memory clinic is not the patient the diagnostic frame assumes. The frame’s failure to test is the injury. The right’s function is to compel the test and, where the test discloses a correctable substrate, to compel the correction.

The horizon is wide because the human cost of not opening it is unbearable, and because the opening is available.

John is a composite. Every element of his file, from the biochemistry to the outcome, is drawn from documented clinical practice and from the peer-reviewed literature identified above. Nothing about him is invented except the combination of the elements in one person. He could be filed tomorrow. He could be filed a hundred thousand times tomorrow, if anyone chose to file him. The instruments already exist. The evidence, on each axis and in the composite, is neither absent nor decisive but points consistently in one direction. What is missing is the frame within which the direction is legally acknowledged.

That frame is what this site is written to invite.